News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MAKO Surgical Corp. Announces Pricing of Initial Public Offering



2/15/2008 8:54:17 AM

FT. LAUDERDALE, Fla., Feb. 14, 2008 (PRIME NEWSWIRE) -- MAKO Surgical Corp. announced today the initial public offering of 5,100,000 shares of its common stock at a price of $10.00 per share, all of which shares are being offered by MAKO Surgical Corp. MAKO Surgical Corp. and a selling stockholder have granted the underwriters a 30-day option to purchase up to an additional 698,333 shares and 66,667 shares, respectively, at the initial public offering price to cover over-allotments, if any. MAKO Surgical Corp.'s common stock will trade on the NASDAQ Global Market under the trading symbol ``MAKO''.

J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated are acting as joint book-running managers for the offering, and Cowen and Company, LLC and Wachovia Capital Markets, LLC are acting as co-lead managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 14, 2008. This offering is being made only by means of a written prospectus. Copies of the final prospectus for the offering, when available, may be obtained from: J.P. Morgan Securities Inc.'s prospectus department at 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (866) 430-0686; or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its advanced robotic-arm solution and implants for minimally invasive orthopedic knee procedures. MAKO's Tactile Guidance System includes an interactive tactile robotics-arm platform that utilizes tactile-guided robotics and patient-specific visualization to prepare the knee joint for the insertion and alignment of resurfacing implants through a keyhole incision. This FDA-cleared surgeon-interactive tactile robotic-arm system allows surgeons to provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty(r) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. MAKO has an intellectual property portfolio of more than two hundred licensed or owned patent applications relating to the areas of computer assisted surgery, haptics, robotics, and implants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:

MAKO Surgical Corp.

Susan M. Verde

954-927-2044 x349

sverde@makosurgical.com

Source: MAKO Surgical Corp


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES